Want to see AIFF full AI Analyst Report?
Firefly Neuroscience (AIFF) AI Stock Analysis
Firefly Neuroscience
(NASDAQ:AIFF)
Overall score reflects heavy weighting toward fundamentals: despite improving revenue and a stronger, debt-free balance sheet, AIFF is still characterized by very large losses and persistent negative free cash flow. Technicals add pressure given the clear downtrend and bearish momentum, while valuation offers limited support due to negative earnings and no dividend. Corporate actions are a small positive but not enough to offset profitability and cash-burn risk.
Firefly Neuroscience (AIFF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $15.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.68M
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 1.57
- Revenue Growth
- 320.33%
- EPS Growth
- 79.09%
- Country
- US
- Employees
- 17
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Software - Application
Firefly Neuroscience Business Overview & Revenue Model
Company Description
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by...
Firefly Neuroscience Financial Statement Overview
Summary
Mixed financial profile. Revenue improved to about $1.8M TTM with positive gross margin (~44.6%) and losses narrowed versus 2025, but profitability remains the central weakness with deeply negative operating/net margins and continued large cash burn (TTM operating cash flow about -$7.0M; free cash flow about -$7.2M). Balance sheet strength helps (equity up to ~$14.7M TTM and $0 total debt), but returns remain very negative (ROE ~-90%).
Income Statement
22NegativeBalance Sheet
64PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80M | 1.14M | 108.00K | 498.00K | 0 | 32.00K |
| Gross Profit | 802.00K | 645.00K | 41.00K | 498.00K | 0 | 32.00K |
| EBITDA | -8.87M | -19.55M | -10.32M | -2.58M | -3.20M | -3.82M |
| Net Income | -9.11M | -19.88M | -10.46M | -2.60M | -3.79M | -4.38M |
Balance Sheet | ||||||
| Total Assets | 16.77M | 10.48M | 4.60M | 2.64M | 135.00K | 953.00K |
| Cash, Cash Equivalents and Short-Term Investments | 9.23M | 2.75M | 1.81M | 2.14M | 58.00K | 653.00K |
| Total Debt | 0 | 0 | 694.00K | 0 | 0 | 1.79M |
| Total Liabilities | 2.10M | 2.84M | 4.98M | 2.53M | 2.25M | 3.97M |
| Stockholders Equity | 14.66M | 7.64M | -375.00K | 109.00K | -2.11M | -3.01M |
Cash Flow | ||||||
| Free Cash Flow | -7.20M | -8.32M | -6.57M | -2.56M | -2.89M | -3.82M |
| Operating Cash Flow | -6.99M | -8.19M | -6.16M | -2.17M | -2.89M | -3.82M |
| Investing Cash Flow | -209.00K | -2.49M | -477.00K | -386.00K | 262.00K | 1.60M |
| Financing Cash Flow | 10.51M | 11.62M | 6.30M | 4.64M | 2.04M | 2.04M |
Firefly Neuroscience Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Negative. The current price of 1.06 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.15, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.22 is Neutral, neither overbought nor oversold. The STOCH value of 56.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIFF.
Firefly Neuroscience Risk Analysis
Firefly Neuroscience disclosed 73 risk factors in its most recent earnings report. Firefly Neuroscience reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksFirefly Neuroscience Peers Comparison
Overall Rating
IRTC53Neutral- AIFF46Neutral
NMTC40Underperform
CGTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| IRTC | 53Neutral | $4.07B | -293.42 | -8.97% | ― | 25.58% | 85.38% |
| AIFF | 46Neutral | $15.69M | -1.56 | -90.17% | ― | 320.33% | 79.09% |
| NMTC | 40Underperform | $8.44M | -1.02 | -126.45% | ― | -1.67% | 7.34% |
| CGTX | 39Underperform | $66.39M | -3.69 | -50.17% | ― | ― | 70.27% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AIFF | Firefly Neuroscience, Inc. | 0.99 | -0.68 | -40.66% | |
| IRTC | Irhythm Technologies | 126.17 | -54.93 | -30.33% | |
| NMTC | Neuroone Medical Technologies Corporation | 0.93 | -3.40 | -78.46% | |
| CGTX | Cognition Therapeutics, Inc. | 0.71 | -0.86 | -54.84% |
Firefly Neuroscience Corporate Events
Firefly Neuroscience Reshapes Finance and Accounting Leadership
NeutralOn September 8, 2026, Firefly Neuroscience’s board of directors terminated Chief Financial Officer Paul Krzywicki, effective September 24, 2026, with the company stating the decision did not stem from disagreements over operations, policies or...
Firefly Neuroscience Expands Incentive Plan, Tightens Capital Structure
PositiveOn August 5, 2026, Firefly Neuroscience stockholders approved an amendment to the 2024 Long-Term Incentive Plan, adding 2,000,000 shares to the pool available for equity awards and updating the plan’s evergreen share replenishment feature. This...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026